128 related articles for article (PubMed ID: 11065147)
1. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
Goossens H
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
[TBL] [Abstract][Full Text] [Related]
2. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types.
Goossens H
J Antimicrob Chemother; 2000 Aug; 46 Suppl B():39-52. PubMed ID: 10969061
[TBL] [Abstract][Full Text] [Related]
3. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
Turner PJ
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
[TBL] [Abstract][Full Text] [Related]
4. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
Pfaller MA; Jones RN
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
[TBL] [Abstract][Full Text] [Related]
5. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
Turner PJ
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
7. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Turner PJ
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Korten V; Ulusoy S; Zarakolu P; Mete B;
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
[TBL] [Abstract][Full Text] [Related]
9. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
Turner PJ
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
[TBL] [Abstract][Full Text] [Related]
11. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
Jones RN; Mendes C; Turner PJ; Masterton R
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
[TBL] [Abstract][Full Text] [Related]
12. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
Patzer JA; Dzierzanowska D; Turner PJ
J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
[TBL] [Abstract][Full Text] [Related]
13. Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programme.
Unal S; Masterton R; Goossens H
Int J Antimicrob Agents; 2004 Feb; 23(2):155-63. PubMed ID: 15013041
[TBL] [Abstract][Full Text] [Related]
14. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
15. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
[TBL] [Abstract][Full Text] [Related]
16. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
Turner PJ
J Antimicrob Chemother; 2000 Aug; 46 Suppl B():9-23. PubMed ID: 10969059
[TBL] [Abstract][Full Text] [Related]
17. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia RodrÃguez JA; Martin R; Soria G; Zapardiel J;
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
[TBL] [Abstract][Full Text] [Related]
18. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.
Jones RN
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():1-8. PubMed ID: 11065144
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).
Turner PJ
Diagn Microbiol Infect Dis; 2004 Dec; 50(4):291-3. PubMed ID: 15582303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
